Today: 20 March 2026
Strategy (MSTR) stock jumps 26% as bitcoin bounces back after bruising earnings drop

Strategy (MSTR) stock jumps 26% as bitcoin bounces back after bruising earnings drop

New York, February 6, 2026, 17:14 EST — Trading after the bell.

  • Strategy shares bounced roughly 26% higher after hours, clawing back losses from the previous session’s steep drop.
  • Bitcoin climbed back over $70,000 after an overnight slide that took it close to $60,000, giving a boost to crypto-related stocks.
  • Traders are now trying to gauge if the bounce will last, after Strategy logged a $12.4 billion quarterly loss linked to shifts in bitcoin prices.

Strategy Inc (MSTR) jumped roughly 26% to $134.93 in Friday’s after-hours session, following bitcoin’s quick snapback after two days of heavy selling that shook crypto-related stocks.

Why does this matter? Strategy acts almost like bitcoin on steroids, and the wild swings this week have spotlighted how it’s funded once again. The firm’s whole play revolves around stacking bitcoin in its treasury, right next to its original enterprise analytics operation. Strategy

Bitcoin took a sharp dive Thursday, briefly dropping a shade above $60,000 overnight. By the U.S. cash close, though, it had bounced back, reclaiming $70,700, Investopedia’s market recap showed. Investopedia

Strategy shares swung between $109.45 and $135.50 on Friday, Nasdaq data showed, with roughly 57.1 million shares changing hands.

After a rough Thursday that saw shares tumble 17%—investors were hit by Strategy’s latest quarterly numbers and a fresh slide in bitcoin—the stock bounced back. Investopedia

Strategy reported a fourth-quarter net loss of $12.4 billion, or $42.93 per diluted share, late Thursday, after chalking up a $17.4 billion unrealized loss tied to its digital assets. Most of that pain was on paper: fair value rules require bitcoin’s price swings to hit earnings, regardless of whether the company actually sold. Strategy

Chief executive Phong Le said the company brought in $25.3 billion in 2025 to “advance our Bitcoin treasury strategy,” pushing total holdings up to 713,502 bitcoins. The firm spent $54.26 billion in all—an average of roughly $76,052 for each coin. Strategy

Strategy CFO Andrew Kang said the company set up a $2.25 billion “USD Reserve” to secure funding for two to three years’ worth of preferred dividends and interest payments. By the close of 2025, cash and cash equivalents totaled $2.3 billion. Strategy

Software was barely a blip compared to the bitcoin headlines. Strategy posted $123 million in fourth-quarter revenue; subscription services jumped 62% year-on-year, but product support slipped. Strategy

The downside is pretty clear. If bitcoin loses momentum, Strategy’s results could take another big hit under fair-value rules, putting its financing and ability to meet preferred payouts under real pressure. Its main “STRC” preferred stock was paying an 11.25% dividend as of early February—lofty, especially if the risk trade sours. Strategy

The turnaround on Friday stretched beyond just Strategy. Shares tied to crypto—MARA Holdings, Coinbase Global, Robinhood Markets—snapped back too, picking up as bitcoin bounced, according to Investopedia. Investopedia

All eyes now turn to bitcoin’s grip on the $70,000 level over the weekend and into Monday’s U.S. hours, with traders watching closely for any new word from Strategy about its capital-raising or BTC stash. Investors are also watching February 28—that’s when the next STRC monthly dividend is set to hit, following the company’s revised dividend adjustment framework. Strategy

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
AI stocks snap back: Nvidia surges, Dow clears 50,000 as Amazon’s AI spend spooks investors
Previous Story

AI stocks snap back: Nvidia surges, Dow clears 50,000 as Amazon’s AI spend spooks investors

Silver price whipsaws as CME hikes margins again; traders eye U.S. jobs and CPI next week
Next Story

Silver price whipsaws as CME hikes margins again; traders eye U.S. jobs and CPI next week

Go toTop